AKR1D1

AKR1D1, also known as Aldo-keto reductase family 1 member D1, is a member of the aldo-keto reductase enzyme family. It plays a crucial role in bile acid metabolism, where it converts cholesterol into bile acids. AKR1D1 deficiency has been linked to congenital bile acid synthesis defects. The protein functions through the regulation of bile acid levels, which in turn affects various signaling pathways, including those related to antitumor immunity. Its dysregulation is associated with liver cancer progression, particularly hepatocellular carcinoma (HCC), and is a subject of interest in drug development for potential therapeutic targets.
In terms of drug development, research has focused on the role of AKR1D1 in liver cancer progression, particularly its impact on bile acid metabolism and antitumor immunity. Studies have shown that loss of AKR1D1 promotes the accumulation of isolithocholic acid, impairing the cytotoxic function of natural killer (NK) cells. This has led to the exploration of strategies to target iso-LCA produced by gut microbiota as a potential therapeutic approach for HCC.